Last updated: 2026-10-03 20:00:01. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Elicio Therapeutics, Inc. (ELTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.92, with a market capitalization of $50.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.71 to $16.00. This page covers its latest market performance, valuation, price trends and company information.
$50.46M | |
$1.95 | |
$24.39 | |
$1.71 | |
$1.92 | |
162.06K | |
438.00K | |
-- | |
$16.00 | |
$1.71 | |
-- | |
-- |
Elicio Therapeutics, Inc. (ELTX) last closed at $1.92 as of 2026-10-02 22:32:00, unchanged from the previous close of $1.92.
During the latest regular trading session, ELTX traded between $1.71 and $24.39, with a volume of 162.06K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Elicio Therapeutics, Inc. (ELTX) moved from $1.88 to $1.92, representing a gain of 2.34% ($0.04).
The stock traded between $1.77 and $2.00 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 277.27 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.5%
ELTX is currently trading at $1.92, placing it 1.5% of the way from its 52-week low of $1.71 to its 52-week high of $16.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Elicio Therapeutics, Inc. (ELTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.